COVID-19 continues to impact millions of people around the world every day…
…and lots of questions still remain unanswered.
The FDA has selected Nanobiosym via a nationwide competition to help find answers, and we need your help.
Do you currently have (or think you might have) COVID?
Have you previously had COVID and still feel symptoms (like fatigue, runny nose, coughing, nausea, or shortness of breath, body aches, etc.)?
Do you have an acute respiratory infection (like the Flu, RSV, COVID, etc.) but received a negative test result from traditional COVID tests (antigen or PCR )?
What to expect:
If you’re considering joining our study, our team of professionals will assess if you’re a good fit. You will then go through a consent process where you’ll have the opportunity to ask questions, followed by instructions via email on next steps.
You’ll first fill out an online questionnaire with questions about your health and medical history. Please note: you must be over 18 years old to participate.
If you qualify for any of our ongoing trials, our team will set up a call with you to review the details of the study so you will know what to expect. If you decide to participate, you’ll sign an electronic form giving written permission for additional screenings and access to your health records.
Once we receive your informed consent, we will send instructions on next steps in the process. The study is observational in nature, and involves check-ins with our team of medical professionals.
Are you a healthcare provider or testing service interested in collaborating with us on this study?
We are seeking partnerships to assist with patient recruitment, logistics, and more.
Study Overview
Using the Nanobiosym Digital Diagnostics Platform, this study aims to provide new insights to better manage the ongoing pandemic, enabling smarter patient triage, personalized precision medicine and data-driven public policies.
Despite historic investment in the fight against COVID-19, deep inadequacies in the US laboratory testing & diagnostic infrastructure remain. The lack of quantitative standards in COVID diagnosis has led to people getting conflicting results from lab to lab and from test to test. At Nanobiosym, we are working to provide people with faster, more accurate, and more reliable results.
For more insight see our CEO’s feature articles in Scientific American Magazine.
Out of a nationwide competition of leading companies and research organizations, the FDA has selected Nanobiosym to conduct a nationwide study to address these challenges, using the Nanobiosym Digital Diagnostics Platform and our high-precision NANO Test™ for COVID 19.
Questions?